These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25732622)

  • 1. Lipoprotein(a)-clinical aspects and future challenges.
    Kurt B; Soufi M; Sattler A; Schaefer JR
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):26-32. PubMed ID: 25732622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
    Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study.
    Klingel R; Heibges A; Fassbender C
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):46-50. PubMed ID: 25644612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
    Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
    Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
    Grützmacher P; Öhm B; Szymczak S; Dorbath C; Brzoska M; Kleinert C
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):22-26. PubMed ID: 28233269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
    Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lp(a): a link between thrombosis and atherosclerosis.
    Scanu AM
    Eur J Epidemiol; 1992 May; 8 Suppl 1():76-8. PubMed ID: 1387094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlipoproteinemia(a): clinical significance and treatment options.
    Berthold HK; Gouni-Berthold I
    Atheroscler Suppl; 2013 Jan; 14(1):1-5. PubMed ID: 23357133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
    Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F;
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):14-20. PubMed ID: 25652812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N; Paragh G; Harangi M
    Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein (a): perspectives from a lipid-referral program.
    Rubenfire M; Vodnala D; Krishnan SM; Bard RL; Jackson EA; Giacherio D; Brook RD
    J Clin Lipidol; 2012; 6(1):66-73. PubMed ID: 22264576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
    Stulnig TM; Morozzi C; Reindl-Schwaighofer R; Stefanutti C
    Curr Atheroscler Rep; 2019 Jul; 21(10):37. PubMed ID: 31350625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipoprotein(a) as a cardiovascular risk factor].
    van Lennep JE; Mulder MT
    Ned Tijdschr Geneeskd; 2011; 155(42):A3582. PubMed ID: 22027461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.
    Koschinsky ML
    Curr Atheroscler Rep; 2005 Sep; 7(5):389-95. PubMed ID: 16105483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
    Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
    Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.